[
  {
    "ts": null,
    "headline": "Merck Takes On Amgen, Regeneron, Lowering Stubbornly High Cholesterol By 60%",
    "summary": "Merck said Saturday its new pill — a potential rival to Regeneron and Amgen — lowered stubbornly high cholesterol by almost 60%.",
    "url": "https://finnhub.io/api/news?id=38c2e182fbe918d935f5fdfe0b56e4be00f0be13755fb4651db912651cd4d2aa",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762630245,
      "headline": "Merck Takes On Amgen, Regeneron, Lowering Stubbornly High Cholesterol By 60%",
      "id": 137384576,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Merck said Saturday its new pill — a potential rival to Regeneron and Amgen — lowered stubbornly high cholesterol by almost 60%.",
      "url": "https://finnhub.io/api/news?id=38c2e182fbe918d935f5fdfe0b56e4be00f0be13755fb4651db912651cd4d2aa"
    }
  },
  {
    "ts": null,
    "headline": "Phase 2 Trials Demonstrating Antithrombotic Effect of Two Novel Regeneron Factor XI Antibodies Presented at American Heart Association Scientific Sessions and Published in The Lancet",
    "summary": "Proof-of-concept trials confirm robust anti-clotting effects for Regeneron’s two mechanistically-distinct antibodies against factor XI, in patients undergoing total knee replacement Trial results consistent with prospective design of these antibodies to have distinct profiles – one to provide stronger anticoagulation and the other to have a lower risk of bleeding – potentially allowing physicians to tailor anticoagulant therapy for patients with different risk profiles Phase 3 trials in patients",
    "url": "https://finnhub.io/api/news?id=7060d6190b5811e30166a13c4ee2e1aa3c6301ec573e117531b1f062b698ae59",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762616760,
      "headline": "Phase 2 Trials Demonstrating Antithrombotic Effect of Two Novel Regeneron Factor XI Antibodies Presented at American Heart Association Scientific Sessions and Published in The Lancet",
      "id": 137384670,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Proof-of-concept trials confirm robust anti-clotting effects for Regeneron’s two mechanistically-distinct antibodies against factor XI, in patients undergoing total knee replacement Trial results consistent with prospective design of these antibodies to have distinct profiles – one to provide stronger anticoagulation and the other to have a lower risk of bleeding – potentially allowing physicians to tailor anticoagulant therapy for patients with different risk profiles Phase 3 trials in patients",
      "url": "https://finnhub.io/api/news?id=7060d6190b5811e30166a13c4ee2e1aa3c6301ec573e117531b1f062b698ae59"
    }
  }
]